Further highly dynamic growth in Asia/Pacific consolidated this reporting region’s position as the region with the largest share of revenue. At €448.2m, revenue was significantly higher than the prior-year figure of €381.7m. This corresponds to an increase of 17.4%. A large part of this growth is attributable to the Chinese market, as well as India, Southeast Asia and South Korea.
In the EMEA region, revenue increased by 3.0% to €363.4m (prior year: €352.7m). Business in the core European markets was largely stable; while there was a decline in the UK and in parts of Southern Europe.
Revenue in the Americas region increased by 6.8%, to €378.2m (prior year: €354.0m). The USA performed well, but South America also achieved an increase during the reporting period, thus accelerating growth compared with the prior year.
Earnings before interest and taxes (EBIT) increased to €180.8m (prior year: €154.3m). This includes a positive special effect from an asset disposal at the Ontario site, amounting to around €7.5m, as already reported in the first quarter of fiscal year 2016/17. The EBIT margin was 15.2% (prior year: 14.2%). After adjustment for special effects, the EBIT margin was 14.8% (prior year: 14.7%).
Earnings per share (EPS) increased significantly to €1.57, compared with €1.21 in the prior year. Contributors to this were the increase in operating profit, as well as positive results from currency hedges, as opposed to negative results in the prior year.
Once again, Carl Zeiss Meditec has set itself ambitious targets for fiscal year 2017/18. Due in particular to the positive development of revenue, the improved product mix and the increased proportion of recurring revenue, Carl Zeiss Meditec AG anticipates an adjusted EBIT margin of between 14% and 16% in fiscal year 2017/18 and in the medium term.